SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-22-012674
Filing Date
2022-05-05
Accepted
2022-05-05 16:22:08
Documents
14
Period of Report
2022-05-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ngm-20220505.htm   iXBRL 8-K 37422
2 EX-99.1 ngm-20220505xexx991.htm EX-99.1 74366
6 GRAPHIC ngmlogoprimarycopya.jpg GRAPHIC 26992
  Complete submission text file 0001628280-22-012674.txt   295670

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ngm-20220505.xsd EX-101.SCH 1893
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ngm-20220505_lab.xml EX-101.LAB 23970
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ngm-20220505_pre.xml EX-101.PRE 12633
8 EXTRACTED XBRL INSTANCE DOCUMENT ngm-20220505_htm.xml XML 11370
Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Filer) CIK: 0001426332 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38853 | Film No.: 22896668
SIC: 2834 Pharmaceutical Preparations